Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B

Goulet-Salmon, B.; Berthe, E.; Franc, Sylvia; Chanel, Stéphane; Galateau-Sallé, Françoise; Kottler, Marie‐Laure; Mahoudeau, J; Reznik, Yves

doi:10.1007/bf03347481

Cited by 20 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38,39 The remaining 3 cases were in even younger male individuals with multiple endocrine neoplasia IIB syndrome. 40,41 Patients were 7, 19, and 22 years of age. Although the data are limited, prostatic carcinoids tend to present with locally advanced disease, including some with regional lymph node metastases, yet still have a favorable prognosis.…”

Section: Carcinoid Tumormentioning

confidence: 99%

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

Epstein

Amin

Beltran

et al. 2014

American Journal of Surgical Pathology

455

489

View full text Add to dashboard Cite

On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine differentiation in prostate cancer. The committee consisted of genitourinary oncologists, urologists, urological surgical pathologists, basic scientists, and translational researchers, with expertise in this field. It was concluded that the proceedings of the meeting should be reported in 2 manuscripts appealing to different target audiences, one to focus on surgical pathology and the other to review the molecular aspects of this disease. New clinical and molecular data emerging from prostate cancers treated by contemporary androgen deprivation therapies, as well as primary lesions, have highlighted the need for refinement of diagnostic terminology to encompass the full spectrum of neuroendocrine differentiation. It is envisioned that specific criteria associated with the refined diagnostic terminology will lead to clinically relevant pathologic diagnoses that will stimulate further clinical and molecular investigation and identification of appropriate targeted therapies.

show abstract

Section: Carcinoid Tumormentioning

confidence: 99%

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

Epstein

Amin

Beltran

et al. 2014

American Journal of Surgical Pathology

455

489

View full text Add to dashboard Cite

show abstract

“…46,47 Furthermore, cellular aggregates with variably interspersed eosinophilic NE granules, that is, Paneth cell-like change, may also convey an impression of carcinoid tumor 2 (Figures 2c-f). A careful read of the literature shows that outside those occurring in young patients with multiple endocrine neoplasia syndromes, 48,49 nearly all "prostatic carcinoids" are actually PCa with "carcinoid-like" morphologic features 50,51 and in fact, most of these cases exhibit PSA and NE marker labeling, as well as admixed usual acinar adenocarcinoma. To be labeled a true prostatic carcinoid-akin to the well-differentiated NE tumors in other organs 17 -tumors must exhibit typical carcinoid architecture and cytology, PSA negativity and absence of admixed adenocarcinoma.…”

Section: Prostatic Adenocarcinoma With Focal Ne Marker-positive Cellsmentioning

confidence: 99%

Neuroendocrine tumors of the prostate

Fine

2018

Modern Pathology

View full text Add to dashboard Cite

Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating NE tumors involving the prostate from secondary involvement are highlighted.

show abstract

“…Thyroid medullary carcinomas accompany these syndromes [13,14]. In addition, prostate carcinomas have been reported to make metastases in thyroid follicular adenomas in a very limited number of cases that had applied to relevant clinics with nodular goiter diagnoses and fine needle aspiration cytology (FNAC) is diagnostic [15].…”

Section: Discussionmentioning

confidence: 98%